agreement LPLchip
-
AMT Starts Development of LPLD Diagnostic Tool
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma have entered into a development and commercialization agreement for LPLchip, a diagnostic tool to rapidly diagnose patients with complete and partial Lipoprotein Lipase Deficiency (LPLD).…
agreement LPLchip | 13 November 2009
